# Uniform Multidrug Therapy Regimen for Leprosy Patients

> **NCT00669643** · PHASE4 · COMPLETED · sponsor: **University of Brasilia** · enrollment: 859 (actual)

## Conditions studied

- Leprosy

## Interventions

- **DRUG:** PB 6 doses - Rifampicin and Dapsone
- **DRUG:** PB 6 doses - Rifampicin, Clofazimine and Dapsone
- **DRUG:** MB 12 doses - Rifampicin, Clofazimine and Dapsone
- **DRUG:** MB 6 doses - Rifampicin, Clofazimine and Dapsone

## Key facts

- **NCT ID:** NCT00669643
- **Lead sponsor:** University of Brasilia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2012-09
- **Final completion:** 2016-12-31
- **Target enrollment:** 859 (ACTUAL)
- **Last updated:** 2017-06-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669643, "Uniform Multidrug Therapy Regimen for Leprosy Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00669643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*